SOMERSET, N.J., Feb. 19, 2013 /PRNewswire/ -- Terumo
Interventional Systems, a business unit of Terumo Medical
Corporation, today announced the launch of a new, dedicated group
focused on direct sales, marketing, support and distribution of key
products to the urological specialty beginning April 1, 2013.
The move is part of the company's commitment to strengthening a
direct relationship with urologists nationwide that currently use
its market-leading GLIDEWIRE® Hydrophilic Guidewire
family of products. GLIDEWIRE® guidewires have
captured 94 percent of the Hydrophilic guidewire market and are
used in about one-third of all minimally invasive urological
procedures in the U.S. GLIDEWIRE® guidewires are
valued for consistent performance and fast, reliable access
management. This new strategy marks the end of a distribution
agreement of GLIDEWIRE® guidewire products to U.S.
urology customers between Boston Scientific Corporation and Terumo
Interventional Systems.
"Terumo Interventional Systems is extremely excited about taking
our urology business direct and we are committed to meeting the
growing demands of this important customer base," said James Rushworth, President, Terumo
Interventional Systems and Onset Medical Corporation. "Combined
with our recent acquisition of Onset Medical, we are poised to
offer innovative access systems to the urology specialty and intend
to leverage world-class technology with our existing robust
distribution, supply, and service capabilities to forge strong
physician relationships. Terumo Interventional Systems plans to
introduce a steady stream of devices inspired by clinical
performance, economic advantages, and improved quality of life for
patients."
About the Urology Market
According to market research by Millennium Research Group, Inc.,
the expanding U.S. urological device market is expected to reach
$2.3 billion by 2016. Each year,
approximately 685,000 patients undergo kidney stone management
procedures and the number is expected to steadily increase as more
patients and physicians opt for minimally invasive treatments.
Terumo Interventional Systems has already begun notifying
urology customers of the transition and is providing assistance to
ensure uninterrupted product supply, service, and support.
For additional information about Terumo Interventional Systems
and its products, visit www.terumois.com or contact
Robert Murphy, Jitsu Public
Relations, at (908) 276-0777 or contact@jitsupr.com.
Terumo Interventional Systems
Terumo Interventional
Systems (TIS) is a strategic business unit of Terumo Medical
Corporation. As a market leader in entry site management and lesion
access, TIS is committed to pursuing unique technologies designed
to enhance treatment of coronary and peripheral endovascular
diseases as well as driving strategic initiatives focused on
Critical Limb Ischemia, Complex Coronary Intervention and
Transradial Access.
TIS directly markets a full line of guidewires, catheters,
introducer sheaths, guiding sheaths and embolization products for
use in a multitude of different interventional procedures.
Terumo Medical Corporation
Founded in 1972 as a Terumo
Corporation subsidiary, Terumo Medical Corporation (TMC) develops,
manufactures, and markets a complete, solutions-based portfolio of
high-quality medical devices used in a broad range of applications
for numerous areas of the healthcare industry. TMC is
comprised of two business divisions: Terumo Interventional
Systems and Terumo Medical Products. The company places a premium
on providing customers with world-class products, training and
education programs that drive clear economic value, better clinical
outcomes and improved Quality of Life for patients.
Terumo Corporation
Tokyo-based Terumo Corporation is one of the
world's leading medical device manufacturers with
$5 billion in sales and operations in
more than 160 nations. Founded in 1921, the company develops,
manufactures, and distributes world-class medical devices including
products for use in cardiothoracic surgery, interventional
procedures, and transfusion medicine; the company also manufactures
a broad array of syringe and hypodermic needle products for
hospital and physician office use. Terumo contributes to society by
providing valued products and services to the healthcare market and
by responding to the needs of healthcare providers and the people
they serve.
Terumo Corporation's shares are listed on the first section of
the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>,
or Bloomberg 4543: JP) and is a component of the Nikkei 225,
Japan's leading stock index.
SOURCE Terumo Interventional Systems
